Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 0.61 |
| ▸ | CCR3 | P51677 | 20/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718927 | 0.92 | HRH1 (0.72) | HRH1CCR3KCNH2 | |
| SCHEMBL6242779 | 0.89 | HRH1 (0.72) | HRH1CCR3KCNH2 | |
| SCHEMBL20570794 | 0.89 | HRH1 (0.50) | HRH1CCR3KCNH2 | |
| SCHEMBL10606839 | 0.88 | HRH1 (0.58) | HRH1CCR3KCNH2 | |
| Butane SCHEMBL6989846 | 0.88 | CCR3 (0.51) | HRH1CCR3KCNH2 | |
| SCHEMBL22462743 | 0.87 | HRH1 (0.49) | HRH1CCR3KCNH2 | |
| SCHEMBL215117 | 0.87 | HRH1 (0.49) | HRH1CCR3KCNH2 | |
| SCHEMBL27900147 | 0.87 | HRH1 (0.49) | HRH1CCR3KCNH2 | |
| SCHEMBL14413679 | 0.87 | HRH1 (0.57) | HRH1CCR3KCNH2 | |
| SCHEMBL21722932 | 0.86 | HRH1 (0.48) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946225-B2 | Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2015-02-03 | — | — | US | claimed |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2012-07-12 | — | — | US | claimed |
| EP-2462121-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | Pierre Fabre Médicament (FR) | 2012-06-13 | — | — | EP | claimed |
| EP-2462121-B1 | DERIVATIVES OF 2H PYRIDAZIN-3-ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PF MEDICAMENT (FR) | 2015-02-18 | — | — | EP | disclosed |
| US-8946225-B2 | Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2015-02-03 | — | — | US | disclosed |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2012-07-12 | — | — | US | disclosed |
| EP-2462121-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | Pierre Fabre Médicament (FR) | 2012-06-13 | — | — | EP | disclosed |
| US-7348341-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2008-03-25 | — | — | US | disclosed |
| US-7307090-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-12-11 | — | — | US | disclosed |
| US-7304077-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-12-04 | — | — | US | disclosed |
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| US-6518286-B1 | Piperidinyl compounds for modulation of immune and inflammatory responses in various diseases and disorders, including asthma | ASTRAZENECA AB (SE) | 2003-02-11 | — | — | US | disclosed |
| WO-2003004487-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
| EP-1274701-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
| WO-2002020484-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
| EP-1165545-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001077101-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
| WO-2000058305-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 39/4885CCR3 1/4885KCNH2 4084/4885 |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | SCD, SCD5, CYP2S1 | HRH1 1017/4885CCR3 1668/4885KCNH2 1397/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 38/4885CCR3 1/4885KCNH2 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.